GLPBio

Signaling Pathways

Research Area, Signaling Pathways | GlpBio Life Science Products Suppliers

Read More about this category

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs. At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development.

ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells. Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs. Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug. First generation ADCs made use of early cytotoxins such as the anthracycline, doxorubicin or the anti-metabolite/antifolate agent, methotrexate. Current cytotoxins have far greater potency and can be divided into three main groups: auristatins, maytansines and calicheamicins.

The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.

References:

[1] Tsuchikama K, et al. Protein Cell. 2016 Oct 14. DOI:10.1007/s13238-016-0323-0.

[2] Peters C, et al. Biosci Rep. 2015 Jun 12;35(4). pii: e00225. doi: 10.1042/BSR20150089.

Research Areas

Products Related to Signaling Pathways(40698)

  • GC81715 structure
    GC81715Corey lactone benzoate impurity 1 (Standard)
    CAS: 1215192-62-3
    Purity: >96.00%

    (3aR,4R,5R,6aS)-2-Oxo-4-((R,E)-3-oxo-4-(m-tolyl)pent-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-5-yl benzoate (Standard) is the analytical standard of (3aR,4R,5R,6aS)-2-Oxo-4-((R,E)-3-oxo-4-(m-tolyl)pent-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-5-yl benzoate.

  • GC81716 structure
    GC817163-(Octanoyloxy)propane-1,2-diyl bis(decanoate) (Standard)
    CAS: 82426-88-8
    Purity: >98.00%

    3-(Octanoyloxy)propane-1,2-diyl bis(decanoate) (Standard) is the analytical standard of 3-(Octanoyloxy)propane-1,2-diyl bis(decanoate).

  • GC81717 structure
    GC81717Rivaroxaban impurity 7 (Standard)
    CAS: 1429334-00-8
    Purity: >95.00%

    Rivaroxaban impurity 7 (Standard) is the analytical standard of Rivaroxaban impurity 7.

  • GC81718 structure
    GC81718Ticagrelor impurity 7 (Standard)
    CAS: 274693-39-9
    Purity: >95.00%

    Ticagrelor impurity 7 (Standard) is the analytical standard of Ticagrelor impurity 7.

  • GC81719 structure
    GC817194-Chloro-2-(trifluoroacetyl)aniline
    CAS: 154598-53-5
    Purity: >98.00%

    4-Chloro-2-(trifluoroacetyl)aniline (Compound 10), an analog of Efavirenz, is a Pregnane X receptor (PXR) ligand.

  • GC81720 structure
    GC81720DDO3602
    Purity: >98.00%

    DDO3602 is a PARP1 HSPTAC ( HSP90 -mediated proteolysis-targeting chimera) degrader, with a DC 50 of 490.3 nM against PARP1; its K d values for PARP1 and HSP90 are 66.5 nM and 1.64 nM, respectively.

  • GC81721 structure
    GC81721Ivabradine
    CAS: 155974-00-8
    Purity: >99.50%

    Ivabradine is a potent and orally active HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits the cardiac pacemaker current (If).

  • GC81722 structure
    GC81722pan-HCN-IN-1
    CAS: 1334308-63-2
    Purity: >99.50%

    pan-HCN-IN-1 is a potent HCN ion channel inhibitor with IC 50 values of 58 nM, 522 nM, 58 nM, and 58 nM against HCN1, HCN2, HCN3, and HCN4, respectively.

  • GC81723 structure
    GC81723Saviprazole
    CAS: 121617-11-6
    Purity: >96.00%

    Saviprazole (HOE-731) is a H +,K + -ATPase inhibitor.

  • GC81724 structure
    GC81724Pyrimidinone 8
    CAS: 65004-42-4
    Purity: >99.50%

    Pyrimidinone 8 is a reversible linear non-competitive inhibitor of divalent metal transporter 1 ( DMT1 ), with a K i of 20 μM ( hDMT1 ).

  • GC81725 structure
    GC81725TRPV1 antagonist 10
    CAS: 896584-55-7
    Purity: >98.50%

    TRPV1 antagonist 10 is an orally active and potent TRPV1 antagonist ( IC 50 = 33.06 nM), moderate to weak URAT1 ( IC 50 = 22.51 μM) and GLUT9 (60.25% at 50 μM) inhibitor.

  • GC81726 structure
    GC81726VUANT1
    CAS: 663212-40-6
    Purity: >98.50%

    VUANT1 (VU0183254) is an allosteric antagonist of insect odorant receptor ion channels, which has the activity of inhibiting insect odorant receptor signaling.

  • GC81727 structure
    GC81727HOR1-C59
    CAS: 189574-20-7
    Purity: >99.50%

    HOR1-C59 is a highly selective Or5v1/Olfr110 agonist with an EC 50 of 7.12 nM.

  • GC81728 structure
    GC81728TTFB
    CAS: 352560-76-0
    Purity: >98.00%

    TTFB (N-(4-tert-butyl-1,3-thiazol-2-yl)-3-fluorobenzamide) is a selective, non-competitive zinc-activated channel ( ZAC ) antagonist.

  • GC81729 structure
    GC81729Neuropeptide W-30 (rat) acetate
    Purity: >98.00%

    Neuropeptide W-30 (rat) is an important stress mediator in the central nervous system that modulates the hypothalamus-pituitary-adrenal (HPA) axis and sympathetic outflow.

  • GC81730 structure
    GC81730Misitatug blivedotin
    Purity: >98.00%

    Misitatug blivedotin (RC88) is an antibody-drug conjugate ( ADC ) targeting mesothelin ( MSLN ).

  • GC81731 structure
    GC81731Hericene A
    CAS: 157207-54-0
    Purity: >98.50%

    Hericene A is an orally active aromatic hericene derivative.

  • GC81732 structure
    GC81732iAfaPhos1
    Purity: >98.00%

    iAfaPhos1 is a FKBP12F36V epimer ligand.

  • GC81733 structure
    GC81733APS-2-79 (Standard)
    CAS: 2002381-25-9
    Purity: >98.00%

    APS-2-79 (Standard) is the analytical standard of APS-2-79.

  • GC81734 structure
    GC81734UCB1244283
    CAS: 300587-89-7
    Purity: >99.50%

    UCB1244283 is a synaptic vesicle glycoprotein 2A ( SV2A ) allosteric modulator.

  • GC81735 structure
    GC81735Tinlarebant
    CAS: 1821327-95-0
    Purity: >98.00%

    Tinlarebant (LBS-008) is an orally active non-retinoid RBP4 (retinol-binding protein 4) antagonist.

  • GC81736 structure
    GC81736(αR)-BI-9787
    CAS: 3043939-19-8
    Purity: >99.00%

    (αR)-BI-9787 is the epimer of BI-9787.

  • GC81737 structure
    GC81737Hydrocortisone phosphate sodium (Standard)
    CAS: 6000-74-4
    Purity: >98.00%

    Hydrocortisone phosphate sodium (Standard) is the analytical standard of Hydrocortisone phosphate sodium.

  • GC81738 structure
    GC81738URAT1 inhibitor 7
    CAS: 1632002-28-8
    Purity: >98.00%

    URAT1 inhibitor 7 (compound 10f) is a potent URAT1 inhibitor, with an IC 50 of 12 nM.